المؤلفون: Sherko Kuemmel, Catherine Harper-Wynne, Yeon Hee Park, Fábio Franke, Michelino de Laurentiis, Eva Schumacher-Wulf, Daniel Eiger, Sarah Heeson, Andrés Cardona, Özgür Özyilkan, Flavia Morales-Vàsquez, Ciara Metcalfe, Marc Hafner, Eleonora Restuccia, Joyce O’Shaughnessy

المصدر: BMC Cancer, Vol 24, Iss 1, Pp 1-14 (2024)

مصطلحات موضوعية: Giredestrant, Pertuzumab, Trastuzumab, HER2-positive, Estrogen receptor-positive, Breast cancer, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282

وصف الملف: electronic resource

العلاقة: https://doaj.org/toc/1471-2407Test

الوصول الحر: https://doaj.org/article/e5f45a7c5b7e4bb7bb99b0bb30af3b2cTest

المؤلفون: Kuemmel S., Harper-Wynne C., Park Y. H., Franke F., de Laurentiis M., Schumacher-Wulf E., Eiger D., Heeson S., Cardona A., Ozyilkan O., Morales-Vasquez F., Metcalfe C., Hafner M., Restuccia E., O'Shaughnessy J.

المساهمون: Kuemmel, S., Harper-Wynne, C., Park, Y. H., Franke, F., de Laurentiis, M., Schumacher-Wulf, E., Eiger, D., Heeson, S., Cardona, A., Ozyilkan, O., Morales-Vasquez, F., Metcalfe, C., Hafner, M., Restuccia, E., O'Shaughnessy, J.

مصطلحات موضوعية: Breast cancer, Estrogen receptor-positive, Giredestrant, HER2-positive, Pertuzumab, Trastuzumab

العلاقة: info:eu-repo/semantics/altIdentifier/wos/WOS:001232654400005; volume:24; issue:1; journal:BMC CANCER; https://hdl.handle.net/11588/963524Test; info:eu-repo/semantics/altIdentifier/scopus/2-s2.0-85194219427

الإتاحة: https://doi.org/10.1186/s12885-024-12179-9Test
https://hdl.handle.net/11588/963524Test

المؤلفون: Jun Liang (251318), Jason R. Zbieg (1892965), Robert A. Blake (8974823), Jae H. Chang (1429789), Stephen Daly (2430460), Antonio G. DiPasquale (1274730), Lori S. Friedman (166879), Thomas Gelzleichter (11113391), Matthew Gill (589302), Jennifer M. Giltnane (11113394), Simon Goodacre (1577413), Jane Guan (166826), Steven J. Hartman (10157036), Ellen Rei Ingalla (8908757), Lorn Kategaya (11113397), James R. Kiefer (1443889), Tracy Kleinheinz (1845637), Sharada S. Labadie (1833826), Tommy Lai (2572615), Jun Li (6494), Jiangpeng Liao (1947631), Zhiguo Liu (594653), Vidhi Mody (8908760), Neville McLean (2128303), Ciara Metcalfe (8908763), Michelle A. Nannini (11113400), Jason Oeh (1845505), Martin G. O’Rourke (11113403), Daniel F. Ortwine (1600621), Yingqing Ran (2100610), Nicholas C. Ray (3064926), Fabien Roussel (3030714), Amy Sambrone (1551289), Deepak Sampath (640340), Leah K. Schutt (11113406), Maia Vinogradova (8908772), John Wai (1503217), Tao Wang (12008), Ingrid E. Wertz (11113409), Jonathan R. White (11113412), Siew Kuen Yeap (1346391), Amy Young (251900), Birong Zhang (1947472), Xiaoping Zheng (566379), Wei Zhou (24328), Yu Zhong (291917), Xiaojing Wang (147040)

مصطلحات موضوعية: Cell Biology, Genetics, Neuroscience, Pharmacology, Biotechnology, Cancer, Infectious Diseases, Chemical Sciences not elsewhere classified, Information Systems not elsewhere classified, Exceptional Preclinical Profile, dose, Bioavailable, human, candidate, combination, liability, Phase, Orally, antagonist, Breast Cancer Breast cancer, wild-type ER α tumor model, GDC -9545, estrogen receptor degrader, antiproliferation, SERD, interaction, Estrogen Receptor Antagonist, giredestrant, Fine-tuning, PDX

العلاقة: https://figshare.com/articles/journal_contribution/GDC-9545_Giredestrant_A_Potent_and_Orally_Bioavailable_Selective_Estrogen_Receptor_Antagonist_and_Degrader_with_an_Exceptional_Preclinical_Profile_for_ER_Breast_Cancer/14959973Test

الإتاحة: https://doi.org/10.1021/acs.jmedchem.1c00847.s001Test